Jump to:
Joe Muller is a member of the emerging companies & venture capital practice at Ropes & Gray. He advises life sciences and technology companies and venture capital, private equity, institutional and strategic investors on formation and startup matters, venture capital, growth equity and other minority equity financing transactions, general corporate and governance matters, and a variety of strategic transactions.
Experience
Representative Emerging Company Engagements
- Represented Camp4 Therapeutics in its $100 million Series B financing and in ongoing corporate and financing matters.
- Represented Creyon Bio in a global licensing and multi-target research collaboration with Eli Lilly and in ongoing corporate and financing matters.
- Represented Dash Bio in formation and in raising $17.5 million in initial funding, and in ongoing corporate and financing matters.
- Represented Hertha Metals in ongoing corporate and financing matters, including in raising more than $17 million in initial funding.
- Represented Solarea Bio in its Series A and Series B financings, and in ongoing corporate and financing matters.
Representative Investor Engagements
- Represented Baillie Gifford Overseas Limited in various venture and growth equity investments, including in its investment in Rippling’s $450 million Series G financing and associated employee tender offer.
- Represented BlackRock in leading a minority investment of over $90 million in MACRO, a multiplatform media company.
- Represented Collaborative Fund in various transactions, including in its investments in Anthro Energy, Bandit Running, Dandelion Energy, Endolith, Phaidra, Rubi Laboratories and Smash Kitchen.
- Represented Crosspoint Capital Partners in various transactions, including in leading investments in Afero, Everseen, ReversingLabs and SynthBee and in other matters, including in establishing and administering the RSAC Innovation Sandbox investment program.
- Represented Partners Group in acquiring a significant minority stake in restor3d, a leader in technology-driven personalized orthopedic solutions, and in other transactions.
- Represented Perceptive Xontogeny Venture Funds in a strategic partnership with Lexeo Therapeutics and venBio Partners to develop novel RNA-based therapeutics through a new entity backed by up to $40 million in private equity financing from Perceptive and venBio.
- Represented Pfizer in a novel strategic partnership with Flagship Pioneering, valued at up to $7 billion, to create a new pipeline of innovative medicines; represented Pfizer Ventures in various transactions.
- Represented a biotechnology company in establishing a joint venture with a global pharmaceutical company.
- Represented a global pharmaceutical company in a cross-border “build-to-buy” transaction.
- Represented a leading institutional investor in 20+ venture and growth equity investments while working in-house on secondment from Ropes & Gray; regularly represents the same institutional investor in various transactions.